KNSA Stock Summary and Trading Ideas (Kiniksa Pharmaceuticals International PLC - Class A | NASDAQ:KNSA)

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Kiniksa Pharmaceuticals International PLC - Class A trades on the NASDAQ stock market under the symbol KNSA.

As of June 18, 2026, KNSA stock price climbed to $55.11 with 702,285 million shares trading.

KNSA has a beta of -0.47, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.02 to the broad based SPY ETF.

KNSA has a market cap of $4.24 billion. This is considered a Mid Cap stock.

Last quarter Kiniksa Pharmaceuticals International PLC - Class A reported $214 million in Revenue and $.27 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.11.

In the last 3 years, KNSA traded as high as $59.87 and as low as $13.56.

The top ETF exchange traded funds that KNSA belongs to (by Net Assets): VTI, VB, VBK, DFAS, DFMC.

KNSA has outperformed the market in the last year with a price return of +97.2% while the SPY ETF gained +26.2%. KNSA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.2% and +15.2%, respectively, while the SPY returned +11.6% and -1.0%, respectively.

KNSA support price is $52.78 and resistance is $55.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.